ArticleNature immunology2024
Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism.
Abstract read
In one paragraph
Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers.
0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed.
- Trial
- Molecular mechanisms and targeted therapeutic strategies for glycolytic reprogramming in osteosarcoma.Genes & diseases · 2027Review
- Boosting CAR T cell efficacy in cancer with metabolic insights from design to diet.Nature reviews. Cancer · 2026Review
- CD112 Lactylation Drives Dual Immune Evasion From CD8+ T Cells and NK Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- ATF6-mediated GTPase RHOQ promotes liver cancer progression via enhancing aerobic glycolysis through PAK1 phosphorylation.Clinical and translational medicine · 2026Article
- Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review).International journal of oncology · 2026Review
- [A transition from targeting immune evasion to a multidisciplinary collaborative treatment framework for "homotherapy for heteropathy" in liver metastases].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Metabolic reprogramming-mediated therapeutic resistance in renal cell carcinoma: Mechanisms and targeted intervention strategies.iScience · 2026Review
- Review
- Lactylation Remodels Tumorigenesis, Immune Microenvironment, and Therapeutic Response.Current issues in molecular biology · 2026Review
- Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases.Stem cell research & therapy · 2026Review
- Metabolic convergence of diabetes and prostate cancer: from dysglycemia to tumor microenvironment reprogramming.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
- Nanozyme-Mediated Cellular and Microenvironmental Metabolic Reprogramming for Boosting Cancer Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- All-trans retinoic acid suppresses CD8Signal transduction and targeted therapy · 2026Article
- Mitochondrial metabolism and PD-1 blockade: mechanisms and therapeutic opportunities in cancer immunotherapy.Molecular biology reports · 2026Review
- Metabolic rewiring of the dendritic cell-T cell axis: tumour-derived barriers and therapeutic opportunities.Experimental & molecular medicine · 2026Review
- Spatial architecture of immunometabolism: Mitochondrial‑organelle interfaces in immune signaling (Review).International journal of molecular medicine · 2026Review
- Decoding T cell exhaustion in the tumour microenvironment.Experimental & molecular medicine · 2026Review
- The pyruvate transporter hermes regulates autophagy and health by modulating ROS production.Cell reports · 2026Article
- Dual compartment lipid carriers hijack exocytosis to empower natural killer cells against solid tumours.Nature communications · 2026Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Ronal M PeraltaDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Bingxian XieDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Konstantinos LontosTumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Hector Nieves-RosadoDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Kellie SpahrDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Supriya JoshiDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
B Rhodes FordDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Kevin QuannDepartment of Medicine, Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA, USA.
Andrew T FrischDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Victoria DeanDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Mary PhilbinTumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Anthony R CilloDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-3213-3129
Sebastian GingrasDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0003-2607-8642
Amanda C PoholekDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-5587-8940
Lawrence P KaneDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-5198-516X
Dayana B RivadeneiraDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-9483-7036
Greg M DelgoffeDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA. gdelgoffe@pitt.edu.ORCID http://orcid.org/0000-0002-2957-8135
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0MWILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Greg M. Delgoffe · 2004 to 2026
$49.6MTherapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9MTraining in Cellular & Molecular Mechanisms of Tumor RejectionT32CA082084 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Robert J Binder, Dario AA Vignali · 1999 to 2026
$9.2MAutoimmunity and Immunopathology Training ProgramT32AI089443 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHLOMCHIK, MARK J · 2010 to 2024
$6.6MUncovering the metabolic underpinnings of T cell exhaustionR01AI166598 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DELGOFFE, GREG M. · 2022 to 2025
$3.2MDissecting the role of hypoxia in T cell differentiation in cancerR01CA277473 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Greg M. Delgoffe, Yana Najjar · 2023 to 2026
$2.4MMetabolic control of regulatory T cell functional identityR01AI171483 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DELGOFFE, GREG M. · 2022 to 2025
$2.4MExploring and exploiting metabolic plasticity in regulatory T cellsDP2AI136598 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DELGOFFE, GREG M. · 2017 to 2017
$2.3MIlluminating metabolic pathways enabled by early T cell activationR21AI135367 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DELGOFFE, GREG M. · 2018 to 2019
$430kUnderstanding the role of altered lipid metabolism in CD8 T cell exhaustion within the tumor microenvironmentF31CA288000 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Kellie Spahr · 2024 to 2026
$149kMetabolically improving the generation, function, and persistence of therapeutic T cells for the treatment of cancerF31CA257760 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FRISCH, ANDREW · 2021 to 2022
$93kNCI NIH HHS F31 CA257760NCI NIH HHS F31 CA288000NCI NIH HHS P30 CA047904NCI NIH HHS P50 CA097190NCI NIH HHS P50 CA121973NCI NIH HHS R01 CA277473NCI NIH HHS T32 CA082084NIAID NIH HHS DP2 AI136598NIAID NIH HHS F31 AI152429NIAID NIH HHS R01 AI166598NIAID NIH HHS R01 AI171483NIAID NIH HHS R21 AI135367NIAID NIH HHS T32 AI089443U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) F31CA288000U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA277473U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) T32CA082084U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 1F31AI152429-01A1U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) DP2AI136598U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI166598U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI171483U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) T32AI089443
Abstract
CD8
Indexed as
CD8-Positive T-LymphocytesLactic AcidMonocarboxylic Acid TransportersTumor MicroenvironmentAnimalsCell Line, TumorHumansMiceMice, Inbred C57BLMice, KnockoutLactic AcidMonocarboxylic Acid Transporters
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.